trial

A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

NCTId NCT04072354
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 463 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2023-05-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
463 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2019-09-17
Primary completion
2023-05-12
Eligibility
ALL · 13 Years · 65 Years

Interventions & indications

Drugs
Ulotaront

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

53 total
Little Rock, United StatesAnaheim, United StatesBellflower, United StatesLemon Grove, United StatesLong Beach, United StatesMontclair, United StatesPico Rivera, United StatesSan Diego, United StatesHollywood, United StatesHollywood, United StatesMiami Springs, United StatesAtlanta, United States

Linked catalysts

1
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in — primary completion2023-05-12

Facts & assertions

4 sourced
Enrollment
463
Phase
PHASE3
Primary Completion Date
2023-05-12
Status
COMPLETED
relationships
The graph out of here
drug
Ulotaront
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication